SAB Biotherapeutics (NASDAQ:SABS) CEO Eddie Sullivan joined Steve Darling from Proactive to share news the company has present interesting data with its novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies. Sullivan telling Proactive showing its fully-human polyclonal antibody platform maintains its efficacy against multiple variants of several highly mutating viruses. Sullivan says this shows the power of polyclonal antibodies to neutralize highly mutating viruses and what sets SAB’s novel therapeutic products apart from others.
SAB Biotherapeutics releases new data showing fully-human polyclonal efficacy against mutation
